<?xml version="1.0" encoding="UTF-8"?><feed xmlns="http://www.w3.org/2005/Atom">
  <title>CytoCares | wechat-feeds</title>
  <id>https://github.com/hellodword/wechat-feeds</id>
  <updated>2020-12-14T20:20:10+08:00</updated>
  <subtitle>为您传递细胞治疗相关行业信息与技术进展，共同促进国内免疫治疗技术发展与行业繁荣</subtitle>
  <link href="https://github.com/hellodword/wechat-feeds"></link>
  <author>
    <name>hellodword</name>
  </author>
  <entry>
    <title>GITR激动剂单药尽数惨败，MEDI1873停止临床研究！</title>
    <updated>2020-12-14T19:05:21+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-14:/s/fATZK6Udpwu4VhCyn3VAIA</id>
    <link href="https://mp.weixin.qq.com/s/fATZK6Udpwu4VhCyn3VAIA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>抗体药物动态-12月11日</title>
    <updated>2020-12-11T19:54:49+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-11:/s/c1bgfR4nAoFdcbIIkZiuZg</id>
    <link href="https://mp.weixin.qq.com/s/c1bgfR4nAoFdcbIIkZiuZg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>两例经过CART治疗的患者完全缓解！MacroGenics公布Tebotelimab（PD-1 × LAG-3）初步临床数据</title>
    <updated>2020-12-10T19:05:27+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-10:/s/wi_qqS_iebVxYKXknWMEiA</id>
    <link href="https://mp.weixin.qq.com/s/wi_qqS_iebVxYKXknWMEiA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>CAR-T的中国力量</title>
    <updated>2020-12-09T18:56:09+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-09:/s/Gc2BVgQ5RCXHvTQI65YkgA</id>
    <link href="https://mp.weixin.qq.com/s/Gc2BVgQ5RCXHvTQI65YkgA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>抗体药物动态-12月9日</title>
    <updated>2020-12-09T18:56:09+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-09:/s/2_vCY73ukcVp53tgBgzY8A</id>
    <link href="https://mp.weixin.qq.com/s/2_vCY73ukcVp53tgBgzY8A" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>抗体药物动态-12月8日</title>
    <updated>2020-12-08T19:25:33+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-08:/s/VuKwf6YkHz9vyu2leWViqw</id>
    <link href="https://mp.weixin.qq.com/s/VuKwf6YkHz9vyu2leWViqw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>研发启示录！F-star旗下CD137/OX40双靶向激动剂</title>
    <updated>2020-12-07T20:13:22+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-07:/s/vzx6JNfYsZ4O48Ka1OMs8w</id>
    <link href="https://mp.weixin.qq.com/s/vzx6JNfYsZ4O48Ka1OMs8w" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>抗体药物动态-12月7日</title>
    <updated>2020-12-07T20:13:22+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-07:/s/ZqkS9bOKftEe393ZXOJz_Q</id>
    <link href="https://mp.weixin.qq.com/s/ZqkS9bOKftEe393ZXOJz_Q" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>抗体药物动态-12月4日</title>
    <updated>2020-12-04T19:15:37+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-04:/s/BR_z3STYRllghDu8eJUzxQ</id>
    <link href="https://mp.weixin.qq.com/s/BR_z3STYRllghDu8eJUzxQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>间充质干细胞调节免疫和治疗工艺开发</title>
    <updated>2020-12-03T19:06:40+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-03:/s/bb4bCush0pOiydNiS4hedQ</id>
    <link href="https://mp.weixin.qq.com/s/bb4bCush0pOiydNiS4hedQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>抗体肿瘤治疗的亚型选择</title>
    <updated>2020-12-02T19:06:17+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-02:/s/GXmxxiUZ8wT7oR3cbXa1AA</id>
    <link href="https://mp.weixin.qq.com/s/GXmxxiUZ8wT7oR3cbXa1AA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>抗体药物动态-12月2日</title>
    <updated>2020-12-02T19:06:17+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-02:/s/5L4Q5oSpOmaBKzDAp44svA</id>
    <link href="https://mp.weixin.qq.com/s/5L4Q5oSpOmaBKzDAp44svA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>CAR-T克服抑制性肿瘤微环境的策略</title>
    <updated>2020-12-01T18:22:19+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-01:/s/6d6ehYulfSqq6CAPrXF-Yg</id>
    <link href="https://mp.weixin.qq.com/s/6d6ehYulfSqq6CAPrXF-Yg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>抗体药物动态-12月1日</title>
    <updated>2020-12-01T18:22:19+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-01:/s/_o2c1fL9UKQM79UjlSympQ</id>
    <link href="https://mp.weixin.qq.com/s/_o2c1fL9UKQM79UjlSympQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>双特异抗体系列之--DLL3</title>
    <updated>2020-12-01T18:22:19+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-01:/s/EwyEJ-X8Z9031Mslngwjdw</id>
    <link href="https://mp.weixin.qq.com/s/EwyEJ-X8Z9031Mslngwjdw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
</feed>